Clinical trials: Liver
Hepatic Insufficiency
Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)
This open-label, non-randomized study was designed to compare pharmacokinetics of a single 50 milligram (mg) dose of MK-0822 in participants with and without moderate hepatic insufficiency (abnormal liver function) in order to…
- Trial name
- NCT01512693
- Testing
- MK-0822
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Administration of the farnesoid X receptor (FXR) ligand obeticholic acid (OCA) for 72 weeks to subjects with biopsy evidence of nonalcoholic steatohepatitis (NASH) will result in improvement in their liver disease as measured by…
- Trial name
- FLINT (NCT01265498)
- Testing
- obeticholic acid
- Where
- 9 sites in United States
- Volunteers
- 283 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis Delta
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)
The primary objective of this study is to evaluate the efficacy of bulevirtide administered subcutaneously (SC) for 48 weeks at a dose of 2 mg or 10 mg once daily for treatment of chronic hepatitis delta (CHD) in comparison to…
- Trial name
- NCT03852719
- Testing
- Bulevirtide
- Where
- 19 sites in United States, Germany and 3 more
- Volunteers
- 150 people
- Sponsor
- Gilead Sciences
Hepatitis C
Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)
To determine the relapse rate at 24 weeks follow up in Hepatitis C Virus Genotype 1 Low Viral Load (HCV LVL G1) patients treated for 24 weeks with Peg Intron and Rebetol who are Hepatitis C Virus-Ribonucleic Acid (HCV-RNA)…
- Trial name
- NCT00709228
- Testing
- PegIntron, Rebetol
- Volunteers
- 496 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Hepatocellular Carcinoma, HCC
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
This is a Phase 2 Study of PD-0332991 in the treatment of patients with Advanced Hepatocellular Carcinoma (HCC), a type of adenocarcinoma and the most common type of liver tumor.
- Conditions
- Advanced Hepatocellular Carcinoma, HCC, Liver Cancer
- Trial name
- NCT01356628
- Testing
- PD-0332991
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft…
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02180867
- Testing
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide
- Where
- 381 sites in United States, Canada and 1 more
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
- Trial name
- NCT00865709
- Testing
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Where
- 116 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Hepatitis C Virus (HCV) Infection
Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults
This randomized controlled trial (RCT) will test the efficacy of a Community Health Worker/Registered Nurse (CHW-RN) HCV intervention for homeless individuals, many who are also drug users.
- Trial name
- NCT04513899
- Testing
- Community health worker (CHW)/ registered nurse (RN) [CHW/RN], Clinic-based Standard of Care (cbSOC) Program (control group)
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of California, Irvine
NASH With Fibrosis
Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
This is a single-center, single-period, single-dose, open-label, non-randomized study to assess the mass balance recovery, metabolite profile and metabolite identification of 14C- labelled rencofilstat ([14C] CRV431).
- Trial name
- NCT05737433
- Testing
- [14C]-rencofilstat 225mg
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hepion Pharmaceuticals, Inc.
Cancer
Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs
A retrospective cohort study using the LabRx medical claims database will be performed to address these objectives. The primary objective of this project is to examine the background rates of liver function test (LFT)…
- Trial name
- NCT01098500
- Testing
- Tyrosine kinase inhibitors
- Volunteers
- 3,800 people
- Sponsor
- GlaxoSmithKline
Cirrhosis, Liver
Prophylactic Antibiotics in Admitted Cirrhotics
In this pilot study, the investigators aim to assess feasibility of subject identification and data collection, including specimen processing, as well as the rate of enrollment for a future, larger study of the effect of empiric…
- Trial name
- NCT04218695
- Testing
- Ceftriaxone, Normal saline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hepatitis B
A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects
GSK3389404 is being developed for the treatment of CHB virus infection. The development goal for GSK3389404 is the establishment of a finite duration treatment that results in sustained suppression of hepatitis B virus (HBV)…
- Trial name
- NCT03020745
- Testing
- GSK3389404
- Where
- 21 sites in China, Hong Kong and 4 more
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Schizophrenia, Schizoaffective Disorder
Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
The purpose of this study is to evaluate the tolerability and safety of paliperidone ER (extended-release) in doses between 3 milligrams per day and 12 milligrams per day in the treatment of patients with schizophrenia or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00535145
- Testing
- Treatment as usual (TAU), Paliperidone ER
- Where
- 21 sites in United States
- Volunteers
- 121 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Malaria, Plasmodium Falciparum Malaria
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.
- Trial name
- NCT00312702
- Testing
- Falciparum Malaria Protein 11 with AS02A adjuvant
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Hepatitis B, Chronic
An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB)
Objective(s) The primary study objective is to assess the antiviral effect of 12 weeks of adefovir dipivoxil treatment in Korean patients with chronic hepatitis B and compensated liver disease.
- Trial name
- NCT01205165
- Testing
- Adefor dipivoxil
- Volunteers
- 104 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type II, Fatty Liver
Study of INT-747 in Patients With Diabetes and Presumed NAFLD
The primary objectives of this study are to assess, in patients with Type 2 diabetes mellitus (DM) and presumed nonalcoholic fatty liver disease (NAFLD), the following: The safety and tolerability of multiple doses of INT 747…
- Trial name
- NCT00501592
- Testing
- INT-747
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Intercept Pharmaceuticals
NASH - Nonalcoholic Steatohepatitis
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology
The HepQuant SHUNT test, which is provided as a HepQuant SHUNT Liver Diagnostic Kit, is a minimally-invasive test of liver function and physiology which has been designated by the FDA as an investigational drug/device combination…
- Trial name
- NCT03294941
- Testing
- HepQuant SHUNT Liver Diagnostic Kit
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- HepQuant, LLC
Intraoperative Bleeding
Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery
This is a prospective, multicenter, randomized, controlled investigation. Subjects in which bleeding from the exposed parenchymal surface is observed intraoperatively following the ligature of vessels visible with the unaided eye…
- Trial name
- BARRIER (NCT01458561)
- Testing
- BioFoam Surgical Matrix, Gelfoam Plus
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- CryoLife, Inc.
Liver Transplantation
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
The purpose of this trial was to demonstrate the efficacy and safety of everolimus in combination with reduced tacrolimus, compared to tacrolimus control, in living donor liver transplant recipients.
- Trial name
- NCT01888432
- Testing
- Everolimus + reduced tacrolimus, Standard tacrolimus
- Where
- 42 sites in United States, Canada and 11 more
- Volunteers
- 285 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic
SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).
This 2 arm study will evaluate the efficacy and safety of intermittent treatment with PEGASYS in HBeAg negative patients with chronic hepatitis B who have demonstrated virological and biochemical response after treatment with…
- Trial name
- NCT00442572
- Testing
- PEGASYS [peginterferon alfa-2a]
- Where
- Bulgaria
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.